What is a tumor board and should my EGFR-Mutant Lung Cancer case be reviewed by one

Understanding Tumor Boards for EGFR-Mutant Lung Cancer

What Is a Tumor Board?

A tumor board (also called a multidisciplinary tumor board or molecular tumor board) is a team of cancer specialists from different fields who meet together to review and discuss individual patient cases. These experts typically include:

• Medical oncologists (cancer drug specialists)
• Surgical oncologists (cancer surgeons)
• Radiation oncologists (radiation therapy specialists)
• Pathologists (tissue specialists)
• Radiologists (imaging specialists)
• Nurses and other specialists relevant to your cancer type

The team reviews your [ID removed] imaging, pathology reports, and genetic test results to develop treatment recommendations collaboratively.

---

Why Tumor Boards Matter for EGFR-Mutant Lung Cancer

Your EGFR-mutant status is particularly important because it opens up multiple targeted therapy options, and the choice between them can significantly impact your outcomes. According to the NCCN Guidelines for Non-Small Cell Lung Cancer, treatment decisions for EGFR-mutant lung cancer require careful consideration of:

• Which specific EGFR mutation you have (common mutations like exon 19 deletion or L858R vs. uncommon mutations like exon 20 insertions)
• Whether you've received prior EGFR inhibitor therapy and how your cancer responded
• Whether resistance mechanisms have developed (like the T790M mutation)
• Your overall health status and any brain metastases (which are more common in EGFR-mutant lung cancer)

---

Should Your Case Be Reviewed by a Tumor Board?

Yes, a tumor board review is highly recommended for your situation. Here's why:

Treatment Complexity

According to NCCN Guidelines, first-line treatment options for EGFR-mutant lung cancer include:

• Osimertinib (a third-generation EGFR inhibitor) - preferred option
• Erlotinib, afatinib, dacomitinib, or gefitinib - other recommended options
• Potentially combination therapy with chemotherapy in certain cases

A tumor board helps ensure your team selects the best option for YOUR specific mutation type and clinical situation.

Resistance Mechanisms

If your cancer has progressed on prior EGFR therapy, the NCCN Guidelines recommend that a tissue biopsy should be considered at progression to evaluate for:

• T790M mutations (which respond to osimertinib)
• Histologic transformation to small cell lung cancer (~6% of cases)
• Other resistance mechanisms (MET amplification, ERBB2 amplification)

A tumor board can help interpret these complex findings and guide next steps.

Personalized Decision-Making

Research shows that molecular tumor boards improve treatment selection. However, it's important to note that concordance (agreement) between different tumor boards on treatment recommendations is only 44-63%, which highlights why getting a second opinion or seeking a board review at a specialized cancer center can be valuable.

---

How to Request a Tumor Board Review

Steps you can take:

1. Ask your oncologist directly: "Would you recommend my case be reviewed by your hospital's tumor board?"

2. Seek review at a specialized center: Major cancer centers like MD Anderson, Memorial Sloan Kettering, Mayo Clinic, and others have robust tumor board programs specifically for lung cancer.

3. Bring your complete records: Ensure they have:

   • Your pathology report with EGFR mutation details
   • All imaging (CT scans, PET scans, brain MRI if done)
   • Prior treatment history and response information
   • Any liquid biopsy or circulating tumor DNA (ctDNA) results

4. Ask about molecular tumor boards specifically: Some centers have specialized boards that focus on genomic findings and targeted therapy options.

---

Key Questions to Ask Your Oncologist

If a tumor board review is recommended, ask:

1. "What is the specific EGFR mutation I have, and how does this affect my treatment options?"
2. "Will my case be reviewed by a molecular tumor board that specializes in EGFR-mutant lung cancer?"
3. "What are the pros and cons of each first-line treatment option for my specific mutation?"
4. "If I develop resistance to my first treatment, how will you determine what caused it and what to try next?"
5. "Are there clinical trials available for my specific EGFR mutation status?"

---

Important Context

According to the NCCN Guidelines, patients with EGFR-mutant lung cancer have significantly better outcomes with targeted EGFR inhibitors compared to traditional chemotherapy. The median progression-free survival with osimertinib is approximately 18.9 months compared to 10.2 months with earlier-generation inhibitors. However, individual outcomes vary based on your specific mutation type and other factors.

A tumor board review helps ensure your care team is aligned on the best strategy for YOUR unique situation and can help you understand the reasoning behind treatment recommendations.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.